We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report.
- Authors
YI-CHEN LIANG; GANGWU; JING CHENG; DAN-DAN YU; HONG-GE WU
- Abstract
Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor, which is used to treat patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. Dermatological reactions are the most common adverse events associated with gefitinib treatment; other adverse effects, including diarrhea, nausea, stomatitis and an asymptomatic elevation of liver enzymes have also been reported. The present study describes a patient with intestinal obstruction who was successfully undergoing treatment with gefitinib for primary and metastatic neoplasms. Gefitinib-induced intestinal obstruction has not been previously reported; therefore, careful monitoring of gastrointestinal symptoms should be conducted throughout the course of gefitinib-treated malignancies.
- Subjects
GEFITINIB; CANCER treatment; NON-small-cell lung carcinoma; BOWEL obstructions; LIVER enzymes; TUMORS
- Publication
Oncology Letters, 2015, Vol 10, Issue 3, p1277
- ISSN
1792-1074
- Publication type
Article
- DOI
10.3892/ol.2015.3463